Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 5 Urinary Bladder Neoplasms 2 Small Cell Lung Carcinoma 2 Liver Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Urothelial Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Non Small Cell Lung Cancer NSCLC 1 Non - Small Cell Lung Cancer NSCLC 1 Melanoma 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Carcinoma, Renal Cell 1 Carcinoma 1

Interventions

Cisplatin 47 Radiotherapy 37 Fluorouracil 23 Cetuximab 17 pembrolizumab 11 Carboplatin 11 Paclitaxel 8 Docetaxel 8 Radiotherapy, Intensity-Modulated 6 Chemotherapy, Adjuvant 6 Surgical Procedures, Operative 5 Standard of Care 5 nimotuzumab 4 Methotrexate 4 Gabapentin 4 Drug Therapy 4 Afatinib 4 Radiotherapy, Conformal 3 Radiation 3 Porfiromycin 3 Nivolumab 3 Neoadjuvant Therapy 3 Fibroblast Growth Factor 7 3 Bleomycin 3 zalutumumab 2 sargramostim 2 epacadostat 2 Tranexamic Acid 2 Tirapazamine 2 Pilocarpine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Head and Neck Neoplasms × tremelimumab × Clear all

NCT02369874 2021-02-10

EAGLE

AstraZeneca

Phase 3 Completed

736 enrolled 26 charts

Head and Neck Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡